Gold nanorods inhibit respiratory syncytial virus by stimulating the innate immune response

Nanomedicine. 2016 Nov;12(8):2299-2310. doi: 10.1016/j.nano.2016.06.006. Epub 2016 Jul 2.

Abstract

Respiratory syncytial virus (RSV) causes severe pneumonia and bronchiolitis in infants, children and older adults. The use of metallic nanoparticles as potential therapeutics is being explored against respiratory viruses like Influenza, Parainfluenza and Adenovirus. In this study, we showed that gold nanorods (GNRs) inhibit RSV in HEp-2 cells and BALB/c mice by 82% and 56%, respectively. The RSV inhibition correlated with marked upregulated antiviral genes due to GNR mediated TLR, NOD-like receptor and RIG-I-like receptor signaling pathways. Transmission electron microscopy of lungs showed GNRs in the endocytotic vesicles and histological analyses indicated infiltration by neutrophils, eosinophils and monocytes correlating with clearance of RSV. In addition, production of cytokines and chemokines in the lungs indicates recruitment of immune cells to counter RSV replication. To our knowledge, this is the first in vitro and in vivo report that provides possible antiviral mechanisms of GNRs against RSV.

Keywords: Antiviral; Bronchiolitis; Gold nanorods; Nanomedicine; Nanoparticles; Pneumonia.

MeSH terms

  • Animals
  • Gold / administration & dosage
  • Gold / pharmacology*
  • Humans
  • Immunity, Innate*
  • Mice
  • Mice, Inbred NOD
  • Nanotubes*
  • Respiratory Syncytial Virus Infections / drug therapy*
  • Respiratory Syncytial Viruses / drug effects*

Substances

  • Gold